Karolinska Management Changes
This article was originally published in Scrip
Karolinska Development AB has appointed life science investor Viktor Drvota chief investment officer, while the company's deputy CEO and chief scientific officer, Terje Kalland, will retire from both positions – effective Dec. 31, 2015. Drvota was previously head of life science and a senior investment manager at SEB Venture Capital. Prior to this he was a practising cardiologist at Huddinge University Hospital in Stockholm for 11 years and associate professor in cardiology at Karolinska Institute, Stockholm, since 2002.
You may also be interested in...
How to make the most of the wealth of raw data in pharmaceutical R&D is an increasing challenge for the industry. The digital revolution is already having an impact in areas like clinical trials, and pharma is also starting to embrace new technologies in drug discovery.
Technology advancement has brought a wave of change in healthcare, with an increasing number of key pharma players now recognizing the potential of digital – particularly in clinical trials.
This week's roundup includes high-level appointments by Five Prime Therapeutics, Depomed and Gilead Sciences and board appointments by Verseon, Arix Bioscience, and Corbus Pharmaceuticals.